Opinion of the Transparency Council – phenoxymethylpenicillinum
At its meeting on 2 September 2024, the Transparency Council adopted opinion No. 142/2024 on the inclusion in the reimbursement of medicines containing the active substance phenoxymethylpenicillinum with respect to indications for use or dosage or route of administration different from those specified in the Summary of Product Characteristics